Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B.
about
Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or BMusculoskeletal complications of hemophiliaOrthopedic disorders of the knee in hemophilia: A current concept reviewNew developments in the management of moderate-to-severe hemophilia BFuture of coagulation factor replacement therapyAchieving and maintaining an optimal trough level for prophylaxis in haemophilia: the past, the present and the futureHaemophilia Centre certification system across Europe: the Belgian experienceTherapeutic and routine prophylactic properties of rFactor VIII Fc (efraloctocog alfa, Eloctate®) in hemophilia AIndividualized prophylaxis for optimizing hemophilia care: can we apply this to both developed and developing nations?Different impact of factor VIII products on inhibitor development?Once-weekly prophylactic dosing of recombinant factor IX improves adherence in hemophilia BThe History of Clotting Factor Concentrates PharmacokineticsThe evolution of comprehensive haemophilia care in the United States: perspectives from the frontline.Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients.Current and evolving features in the clinical management of haemophiliaReview of antihemophilic factor injection for the routine prophylaxis of bleeding episodes and risk of joint damage in severe hemophilia A.Use of prothrombin complex concentrates and activated prothrombin complex concentrates as prophylactic therapy in haemophilia patients with inhibitors.Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoringGuidelines on replacement therapy for haemophilia and inherited coagulation disorders in Italy.Primary prophylaxis for individuals with severe haemophilia: how many hospital visits could treatment prevent?Recombinant FIXFc: a novel therapy for the royal disease?Using value-of-information methods when the disease is rare and the treatment is expensive--the example of hemophilia A.Clinical utility and patient perspectives on the use of extended half-life rFIXFc in the management of hemophilia B.Methods to treat chronic haemophilic synovitis.Choice of factor concentrates for haemophilia: a developing world perspective.Need for Prophylactic Treatment in Adult Haemophilia A PatientsTreatment of hemophilia B: focus on recombinant factor IX.Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in ItalyPrevalence of clinical hip abnormalities in haemophilia A and B: an analysis of the UDC databaseCorrelation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS.Neonatal helper-dependent adenoviral vector gene therapy mediates correction of hemophilia A and tolerance to human factor VIIIHaemophilia Utilization Group Study: assessment of functional health status in haemophilia.Prophylaxis in developed and in emerging countries.Linking medicine and economics: health economics and quality of life in haemophilia care.Orthopaedic surgery of haemophilia in the 21st century: an overview.Evaluation of outcome of care in patients with haemophilia.Gene therapy for hemophilia A: production of therapeutic levels of human factor VIII in vivo in mice.Approaches to successful total knee arthroplasty in haemophilia A patients with inhibitors.Rationale for a randomized controlled trial comparing two prophylaxis regimens in adults with severe hemophilia A: the Hemophilia Adult Prophylaxis Trial.Profile of efraloctocog alfa and its potential in the treatment of hemophilia A.
P2860
Q24234413-22E7D9E8-A8F7-491A-827E-2EC43E00021FQ24648203-61FABD70-54C9-4F80-9C50-C359C89F86A5Q26747550-7AE7C867-7400-4865-B689-4797CDA96302Q26751323-BD4C5ED7-9559-426A-B4FA-1BAAA5F752D3Q26820824-19F8DD41-C5F1-49CD-8BAC-B49F42D2AED1Q26853631-F7C98608-3F5F-4900-9247-FB7ADC388602Q26866341-1C0672A5-80C8-4711-B6FD-0684ADCB719FQ28075081-5F146520-D514-4D69-9485-20A049908215Q28075208-FABA61E1-69AE-4A32-A5B2-E612677BE2D2Q28075679-594BB1B7-04A2-46F5-BAF8-15CBA4C40246Q28078281-9BC51694-4D7A-4AF2-8809-D32A4B5BD5DFQ30235127-9EB39D31-1373-46E6-8AB6-DA22B477B056Q30249256-F324F7E0-D30C-4BC8-8029-3E3C1673214AQ30539596-89D8D5B7-A92E-4EF8-9EFB-33E690B7614AQ33708976-8598D54D-B699-4563-8109-CE38A86040D4Q33715399-1A47FBBB-695A-410B-B622-674B762FC1B5Q33794089-25D03114-2BA1-4D00-8D1B-B95D79CEAB3EQ33794432-688A3DD3-B9E7-435D-BB5B-D34EE3F80346Q33815761-F3A7FEA9-5E0B-48CB-8147-0F40058B34B5Q33904447-F9845238-18E9-4D67-8CED-53D0B6886FE0Q33968782-015C956A-6447-4481-A5B1-8A244CCD4D2DQ34011908-CA9B1612-13FE-47B4-8990-F31BD27EA821Q34045763-48D15307-25F6-4491-B4AB-79C861E77765Q34117199-096B2896-EF56-4A53-9F11-5C6701DFB99EQ34117224-8A7C8F29-6972-40C6-976E-772308F273DCQ34139334-48239EAC-0FB4-4D48-883D-63F20809860CQ34329068-720C3843-AE41-4A81-A0FB-37733D90C314Q34416394-7159EDC0-D9B8-4A75-B907-8512C9AEB183Q34517864-207DB28F-8BD8-42C4-A2C9-3487E675139FQ34522059-1A777AFD-6808-4F4B-80B2-9A0CB76F4E4CQ34550081-7769B22A-76A2-4925-BB9D-91DC9133904AQ34600730-CC85A72C-2740-4C82-A7CD-AB721E4D6849Q34636878-A2D681BF-44C6-4DFD-BDE3-39D8C32D8632Q34636921-9CA430F2-88A0-43DF-8452-AC8B7CB87F43Q34637056-FF99F266-2BBE-4858-9FF0-FB2E6E62491DQ34637116-6F1C3267-E36C-41F0-9493-A45950A910EBQ34675871-ECDC01D0-E7B0-4C43-B5D5-1CA1D86C94FDQ34801411-D0009CD9-9BFE-4A10-AC30-CCCA4D3B9993Q35311771-11561A47-A394-45CF-9555-BB0AC6B0286CQ35565320-4E65D245-51F0-4C09-B0FC-0F36DA510F95
P2860
Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
1992年學術文章
@zh
1992年學術文章
@zh-hant
name
Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B.
@en
Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B.
@nl
type
label
Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B.
@en
Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B.
@nl
prefLabel
Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B.
@en
Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B.
@nl
P2093
P1476
Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B.
@en
P2093
Berntorp E
Löfqvist T
Nilsson IM
Pettersson H
P356
10.1111/J.1365-2796.1992.TB00546.X
P407
P577
1992-07-01T00:00:00Z